Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $152.0 million.

  • Arcus Biosciences' Other Non-Current Liabilities rose 1176.47% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 1176.47%. This contributed to the annual value of $157.0 million for FY2024, which is 1056.34% up from last year.
  • Per Arcus Biosciences' latest filing, its Other Non-Current Liabilities stood at $152.0 million for Q3 2025, which was up 1176.47% from $159.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Other Non-Current Liabilities peaked at $166.0 million during Q1 2025, and registered a low of $10.2 million during Q1 2021.
  • Over the past 5 years, Arcus Biosciences' median Other Non-Current Liabilities value was $140.0 million (recorded in 2022), while the average stood at $103.2 million.
  • Per our database at Business Quant, Arcus Biosciences' Other Non-Current Liabilities soared by 2236777.16% in 2021 and then plummeted by 620.69% in 2024.
  • Quarter analysis of 5 years shows Arcus Biosciences' Other Non-Current Liabilities stood at $122.0 million in 2021, then grew by 14.75% to $140.0 million in 2022, then rose by 1.43% to $142.0 million in 2023, then rose by 10.56% to $157.0 million in 2024, then dropped by 3.18% to $152.0 million in 2025.
  • Its Other Non-Current Liabilities was $152.0 million in Q3 2025, compared to $159.0 million in Q2 2025 and $166.0 million in Q1 2025.